Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Bortolami

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Melanoma Research|July 20, 2022
Clinical performance indicators for monitoring the management of cutaneous melanoma: a population-based perspectiveAlessandra Buja, Massimo Rugge, Giuseppe De Luca, et al.
Clinical Genitourinary Cancer|March 11, 2023
Estimated Direct Costs of Renal Cancer by Stage of Disease at Diagnosis and Phase of Its Management: A Whole-Disease ModelAlessandra Buja, Giuseppe De Luca, Maura Gatti, et al.
Cancers|February 26, 2025
NON-SMALL-CELL LUNG CANCER: Real-World Population-Based Cohorts' StudyAlessandra Buja, Massimo Rugge, Alberto Bortolami, et al.
Thoracic Cancer|November 21, 2020
Estimated direct costs of non-small cell lung cancer by stage at diagnosis and disease management phase: A whole-disease modelAlessandra Buja, Michele Rivera, Anna De Polo, et al.
European Journal of Dermatology : EJD|November 18, 2021
Quality management of cutaneous melanoma: impact on short-term outcomes and costsAlessandra Buja, Giuseppe De Luca, Manuel Zorzi, et al.
JCO Oncology Practice|December 20, 2019
Use of Electronic Administrative Databases to Measure Quality Indicators of Breast Cancer Care: Experience of Five Regional Oncology Networks in ItalyValentina Guarneri, Paolo Pronzato, Oscar Bertetto, et al.
JCO Oncology Practice|April 7, 2021
Non-Small-Cell Lung Cancer: Real-World Cost Consequence AnalysisAlessandra Buja, Giulia Pasello, Giuseppe De Luca, et al.
The Oncologist|March 23, 2024
Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-WorldGiulia Pasello, Martina Lorenzi, Daniela Scattolin, et al.
Targeted Oncology|June 25, 2022
Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR StudyMarco Maruzzo, Francesco Pierantoni, Alberto Bortolami, et al.
Global & Regional Health Technology Assessment|July 6, 2023
Andrea Marcellusi, Angela Ragonese, Andrea Marinozzi, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Melanoma Research|July 20, 2022
Clinical performance indicators for monitoring the management of cutaneous melanoma: a population-based perspectiveAlessandra Buja, Massimo Rugge, Giuseppe De Luca, et al.
Clinical Genitourinary Cancer|March 11, 2023
Estimated Direct Costs of Renal Cancer by Stage of Disease at Diagnosis and Phase of Its Management: A Whole-Disease ModelAlessandra Buja, Giuseppe De Luca, Maura Gatti, et al.
Cancers|February 26, 2025
NON-SMALL-CELL LUNG CANCER: Real-World Population-Based Cohorts' StudyAlessandra Buja, Massimo Rugge, Alberto Bortolami, et al.
Thoracic Cancer|November 21, 2020
Estimated direct costs of non-small cell lung cancer by stage at diagnosis and disease management phase: A whole-disease modelAlessandra Buja, Michele Rivera, Anna De Polo, et al.
European Journal of Dermatology : EJD|November 18, 2021
Quality management of cutaneous melanoma: impact on short-term outcomes and costsAlessandra Buja, Giuseppe De Luca, Manuel Zorzi, et al.
JCO Oncology Practice|December 20, 2019
Use of Electronic Administrative Databases to Measure Quality Indicators of Breast Cancer Care: Experience of Five Regional Oncology Networks in ItalyValentina Guarneri, Paolo Pronzato, Oscar Bertetto, et al.
JCO Oncology Practice|April 7, 2021
Non-Small-Cell Lung Cancer: Real-World Cost Consequence AnalysisAlessandra Buja, Giulia Pasello, Giuseppe De Luca, et al.
The Oncologist|March 23, 2024
Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-WorldGiulia Pasello, Martina Lorenzi, Daniela Scattolin, et al.
Targeted Oncology|June 25, 2022
Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR StudyMarco Maruzzo, Francesco Pierantoni, Alberto Bortolami, et al.
Global & Regional Health Technology Assessment|July 6, 2023
Andrea Marcellusi, Angela Ragonese, Andrea Marinozzi, et al.
Pageof 3